Manage Your Liver
Q:

Liver protection after hepatitis C treatment is the key to successful recovery

Liver protection after hepatitis C treatment is the key to successful recovery
A:

The launch of direct-acting antivirals (DAAs) in recent years has made a huge impact on the treatment of hepatitis C. Not only has this new option made viral clearance possible for many patients, it also has been proved to have higher success rate than traditional interferon treatment. Studies have shown that DAAs can produce a 90% sustained virologic response (SVR) rates for most HCV genotypes. [1] However, are these DAAs the perfect magic potion patients have been longing for?

 

There is no doubt of the effectiveness of DAAs however there are also shortcomings that cannot be neglected. First, these antiviral drugs were only designed to eradicate the virus; they do not help with the recovery of liver cells, nor can they reverse fibrosis or cirrhosis. Once the virus has been eradicated from the body, the cause of liver damage is removed, but what has been damaged remains damaged. Therefore, even after successful antiviral treatment, the patient must rely on the liver’s self-repair ability to regenerate new healthy liver cells, before normal liver function can resume.

 

Second, recent studies found that DAAs are associated with an increased risk of HCC recurrence. The two different studies indicate that patients infected with hepatitis C virus who received DAA therapy were more likely to experience a recurrence of hepatocellular carcinoma (HCC) or liver cancer than those who had no previous history of the disease. [1] One study pointed out that high recurrence rate of HCC can occur in hepatitis C patients taking these antiviral drugs, especially cirrhotic patients. [2] In another research, a “high rate” of HCC recurrence has also been found in patients who had received prior DAA therapy. [3]

 

In view of the above, the path to recovery and health must not stop at DAAs and eradication of the virus. Close monitoring and follow up is necessary for patients on DAA treatment and those who have achieved SVR, especially those with fibrosis or cirrhosis, as these are the most important risk factors for developing HCC. As mentioned previously, DAAs cannot help to treat fibrosis or cirrhosis. Thus, patients must rely on other methods for recovery and prevention of HCC.

 

One option is YHK, a natural liver therapy from Japan. It has been scientifically proven to help to regenerate healthy liver cells, repair damaged ones as well as prevent or halt cirrhosis. It contains anti-fibrotic properties which can protect and improve liver function. Clinical studies indicate that YHK is effective in reducing ALT and AST levels in patients, normalizing liver function and reversing early liver fibrosis and cirrhosis. [4] In addition, YHK has anti-tumor effects that help to prevent liver cancer. All these properties can help to decrease the risk of liver cancer and liver failure. [5]

 

To date, there is not a single product that can guarantee restoration of liver function and liver health. But with YHK, the shortcomings of DAAs can be compensated. Together, they provide an all-rounded treatment that cover virus clearance and long term protection. “If you don’t treat these patients and ameliorate their liver function, and if hepatocellular carcinoma occurs, you have no chance of curing them. But if you ameliorate liver function and they develop hepatocellular carcinoma, you can cure it better because their improved liver function will allow an ablation.” - Dr Brillanti, investigator of one of the studies. [1] The development of DAAs is no doubt one big step for hepatitis C patients toward health, but post treatment protection such as YHK is also important to ensure long-lasting liver health, especially for patients with cirrhosis.

 

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
A:
With thousands of supplements in the market, and little regulations on supplements, finding a suitable one is difficult enough, let alone finding a SAFE one!   Here we will look at 5 things that you can look for when buying or using supplements, it can help you to avoid risky products and limited the chance of using something unsafe:   1. Look for registrations In some country, there are registration systems on suppl
Hit Questions
A:
YHK has significant effect in stopping liver inflammation; it can enhance the recovery of liver health and protect liver cells. Those who have experienced YHK often have these questions in mind: Why is YHK so different from other liver medicines and supplements? Why is it possible to have such unprecedented effects? The answer seems magical, but in fact, it is not complicated - Because YHK possesses a perfect balance.   To explain this, we must first point out that YH
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
A:
“It isn't fat but rather fibrosis that drives disease progression in people with advanced non-alcoholic steatohepatitis (NASH).”   NASH is one of the most prevalent liver diseases nowadays. NASH is related to non-alcoholic fatty liver disease (NAFLD) which is characterized by the buildup of fat in the liver. Although it is normal to have some fat in the liver, some people might develop inflammation because of this fat accumulation, this is cal
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us